The aim of our retrospective study of real-world data was to investigate whether the presence of additional cytogenetic aberrations and gene mutations have any impact on the outcomes of patients with NPM1- and/or FLT3-ITD mutated AML treated with intensive chemotherapy. The gene discussed is NPM1; the disease is acute myeloid leukemia.